Lymphoma & Plasma Cell Disorders
From the Journals
ASCT may cure follicular lymphoma for some rituximab-naive patients
A retrospective cohort study suggests that ASCT, if performed promptly, can be curative in patients who have had an early failure of first-line...
Conference Coverage
Oral triplet shows promise for relapsed/refractory myeloma
BOSTON – Selinexor plus lenalidomide and dexamethasone proved particularly active in lenalidomide-naive patients.
From the Journals
CAR T-cell therapy found safe, effective for HIV-associated lymphoma
Two HIV-positive patients with chemotherapy-refractory, high-grade B-cell lymphoma achieved complete remission with anti-CD19 CAR T-cell therapy,...
Conference Coverage
Combo could be new standard for transplant-eligible, newly diagnosed myeloma patients
BOSTON – Adding daratumumab to bortezomib, lenalidomide, and dexamethasone improved responses and minimal residual disease negativity.
Conference Coverage
Adding elotuzumab to lenalidomide/dexamethasone can prolong survival in relapsed/refractory myeloma
BOSTON – The overall survival advantage with elotuzumab was observed in all prespecified patient subgroups, including older patients, those with...
Conference Coverage
CT103A elicits responses after prior CAR T-cell relapse
BOSTON – Three of four patients who had failed a prior CAR T-cell therapy achieved a stringent complete response after CT103A.
From the Journals
Worse PFS when radiation is withheld in early-stage Hodgkin lymphoma
Patients negative for disease on PET scans after two chemotherapy cycles fared better with consolidation radiotherapy.
From the Journals
Staging PET/CT better defines extent of mantle cell lymphoma
This type of imaging altered stage and management in nearly one-fifth of cases.
Conference Coverage
Melflufen-dexamethasone active in patients with relapsed/refractory myeloma and EMD
BOSTON – Melflufen plus dexamethasone produced similar response rates in patients with and without extramedullary disease.
Feature
Could home care replace inpatient HSCT?
Researchers are conducting phase 2 trials comparing patients who receive all posttransplant care at home with patients treated in the hospital or...
From the Journals
Study confirms prognostic impact of MYC partner gene in DLBCL
The findings suggest that clinicians should adopt diagnostic strategies to identify this high-risk cohort of patients.